NCT05768958 (TIMEX) is a NA clinical trial of Exercise in Overweight and Obesity, sponsored by Steno Diabetes Center Copenhagen.

Who is sponsoring NCT05768958?

NCT05768958 is sponsored by Steno Diabetes Center Copenhagen.

What drugs are being tested in NCT05768958?

Interventions in NCT05768958: Exercise, Control.

What condition does NCT05768958 study?

NCT05768958 studies Overweight and Obesity, Type 2 Diabetes.

Is NCT05768958 still recruiting?

NCT05768958 is currently active, enrolled. Last updated 30 May 2025.

Last reviewed 2025-05-30 · How we verify

NCT05768958: TIMEX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing

Active, enrolled NA Last updated 30 May 2025

What this trial tests

NA trial testing Exercise in Overweight and Obesity in 58 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 March 2023

Primary endpoint
21 August 2024

31 July 2026

Quick facts

Lead sponsor	Steno Diabetes Center Copenhagen
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	22 March 2023
Primary completion	21 August 2024
Estimated completion	31 July 2026
Sites	1 location across Denmark

Drugs / interventions tested

Exercise
Control

Conditions studied

Overweight and Obesity — all drugs for Overweight and Obesity →
Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Steno Diabetes Center Copenhagen — full company profile →

Who can join

Adults 18 to 75, any sex, with Overweight and Obesity or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D). Furthermore, the aim is to examine the role of hedonic and homeostatic drivers of appetite control in obesity and T2D in the context of meal and exercise timing.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of exercise and exercise timing on energy intake and appetite control in Danish individuals with overweight or obesity with and without type 2 diabetes: a protocol for a randomised controlled cross-over trial.
Jalking L, Launbo NP, Jensen MM, Pedersen HE, et al · · 2025 · cited 1× · PMID 39915022 · DOI 10.1136/bmjopen-2024-092683
Circadian rhythms and gastrointestinal hormone-related appetite regulation.
Malin SK. · · 2025 · PMID 40110812 · DOI 10.1097/med.0000000000000908

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting

Other recruiting trials for Overweight and Obesity

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Other Steno Diabetes Center Copenhagen trials

Trials by the same sponsor.

NCT07485075 — Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical · NA · recruiting
NCT07427251 — The Postprandial Hypo-Avoid Study · Phase 4 · not yet recruiting
NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
NCT06832059 — Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in T · NA · recruiting
NCT07377266 — The Impact of Changing to a New Child- and Family-centered Outpatient Diabetes Clinic Focusing on Early Involvement of t · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05768958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Steno Diabetes Center Copenhagen
Last refreshed: 30 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05768958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing